top of page

Therapeutic Pipeline: Targeting Fibrotic Pathways

Avanti Biosciences is developing first-in-class therapeutics that modulate TGF-β-mediated fibrotic signaling to reverse tissue damage across multiple organs. Our lead program, ABI-171, is the first therapy demonstrating disease reversal in idiopathic pulmonary fibrosis (IPF) - a breakthrough outcome that no approved therapy has achieved.

​

Idiopathic Pulmonary Fibrosis (IPF)

The Disease Challenge
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease characterized by scarring of lung tissue that leads to irreversible decline in lung function. The disease affects approximately 500,000 patients in the United States, with a median survival of only 3-4 years from diagnosis.
Current Treatment Limitations
While three FDA-approved therapies exist these treatments can only slow disease progression. No approved therapy can reverse established lung fibrosis or restore lung function, leaving patients with a devastating prognosis.
Market Opportunity
The IPF therapeutics market is valued at $4.0 billion (2024) and projected to grow to $6.9 billion by 2030, driven by aging demographics, improved diagnosis, and demand for more effective treatments.
Unmet Medical Need
  • No therapy reverses established fibrosis
  • Current drugs have significant side effects (GI, liver toxicity)
  • Median survival remains poor despite treatment
  • Patients need therapies that restore lung function, not just slow decline
lung with microscope.jpg
liver fibr.jpg

NASH-Associated Liver Fibrosis

The Disease Challenge
Metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) is a progressive liver disease that can lead to cirrhosis, liver failure, and hepatocellular carcinoma. Approximately 6 million US adults have significant liver fibrosis (F2-F3 stage) due to NASH, representing a major public health burden.
Current Treatment Limitations
Resmetirom (Rezdiffra®), approved in March 2024, is the first FDA-approved therapy for NASH with moderate-to-advanced fibrosis. However, it demonstrates only 25-30% fibrosis improvement and does not address all patient populations, leaving substantial unmet need.
Market Opportunity
  • Liver Fibrosis Market: $2.3B (2023) → $4.5B (2032)
  • NASH Therapeutics Market: $5.5-7.5B → $15-47.8B by 2032
Unmet Medical Need
  • Limited anti-fibrotic efficacy with current therapy
  • Many patients ineligible for or non-responsive to approved treatment
  • No therapies that effectively reverse liver fibrosis
  • Need for more potent anti-fibrotic agents

Alzheimer's Disease (AD)

The Disease Challenge
Alzheimer's disease (AD) is the most common form of dementia, affecting 6.9 million Americans. The disease causes progressive memory loss and cognitive decline, with devastating impact on patients and caregivers. Despite decades of research, treatment options remain extremely limited.
Current Treatment Limitations
Recently approved anti-amyloid antibodies (lecanemab, donanemab) provide modest clinical benefit but do not address all aspects of AD pathology. Most patients continue to experience disease progression even with treatment.
Market Opportunity
The Alzheimer's therapeutics market is projected to exceed $15 billion by 2030, driven by aging populations and urgent need for disease-modifying therapies that address multiple pathological mechanisms.
Unmet Medical Need
  • Limited disease-modifying therapies available
  • Current treatments address only one pathological pathway (amyloid)
  • Need for therapies targeting alternative mechanisms (tau, neuroinflammation)
  • Oral therapies preferred over chronic infusions
brain.jpg
bottom of page